Riva, M., Rizzo, L., Mancini, V., Greco, R., Bertani, G., Zucchetti, E., et al. (2020). Enasidenib, an Oral Therapy in Mutant IDH2 Relapsed/Refractory Acute Myeloid Leukemia: A Real-Life Single Center Experience. Intervento presentato a: 62nd ASH Annual Meeting and Exposition - Dec 05, 2020 - Dec 08, 2020, San Diego, CA, United States (Virtual, online) [10.1182/blood-2020-141987].

Enasidenib, an Oral Therapy in Mutant IDH2 Relapsed/Refractory Acute Myeloid Leukemia: A Real-Life Single Center Experience

Cairoli R
2020

paper
Hematology
English
62nd ASH Annual Meeting and Exposition - Dec 05, 2020 - Dec 08, 2020
2020
2020
136
S1
20
21
https://ashpublications.org/blood/article/136/Supplement 1/20/473429/Enasidenib-an-Oral-Therapy-in-Mutant-IDH2-Relapsed
none
Riva, M., Rizzo, L., Mancini, V., Greco, R., Bertani, G., Zucchetti, E., et al. (2020). Enasidenib, an Oral Therapy in Mutant IDH2 Relapsed/Refractory Acute Myeloid Leukemia: A Real-Life Single Center Experience. Intervento presentato a: 62nd ASH Annual Meeting and Exposition - Dec 05, 2020 - Dec 08, 2020, San Diego, CA, United States (Virtual, online) [10.1182/blood-2020-141987].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/409344
Citazioni
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 1
Social impact